Related Experiment Videos
Vaniqa--eflornithine 13.9% cream.
1Hair Research and Treatment Centre, and Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada.
Skin Therapy Letter
|May 29, 2001
Summary
Eflornithine HCl 13.9% cream is a new FDA-approved treatment for unwanted facial hair in women. This topical cream works by inhibiting an enzyme essential for hair growth, slowing hair development over several weeks.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Unwanted facial hair (hirsutism) affects many women.
- Limited prescription topical treatments were previously available.
Purpose of the Study:
- To evaluate the efficacy and safety of Eflornithine HCl 13.9% cream for reducing unwanted facial hair in women.
Main Methods:
- Clinical trials were conducted to assess the cream's effectiveness.
- The study involved women seeking treatment for facial hypertrichosis.
Main Results:
- Eflornithine HCl 13.9% cream demonstrated significant hair growth reduction in up to 60% of participants.
- Visible improvements were observed gradually over 4-8 weeks or longer.
- The most common adverse reactions reported were minor skin irritations.
Conclusions:
- Eflornithine HCl 13.9% cream is the first FDA-approved topical prescription for reducing unwanted female facial hair.
- The cream offers a new therapeutic option by inhibiting ornithine decarboxylase (ODC), crucial for hair growth.